NJ Court Deals Another Blow To Drug Industry In Rejecting Novo Nordisk Claims Against IRA

By Gabrielle Wanneh / August 1, 2024 at 5:59 PM
A New Jersey federal district court judge shot down pharmaceutical company Novo Nordisk’s legal challenge against the Medicare drug price negotiation program Wednesday (July 31), rejecting, among other claims challenging the constitutionality of the Inflation Reduction Act, the company’s ultra vires claim that CMS went against statutory text in negotiating new maximum fair prices for more than one of its insulin products. Disappointed with the court's decision to deny its motion for summary judgment, Novo Nordisk plans to immediately...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.